|Real-time Estimate - 01/20 03:59:46 pm|
Fresenius : Kabi launches its first specialty IV drug in the U.S.
|12/01/2020 | 10:21am|
Icatibant injection, an FDA-approved and cost-effective alternative to treat acute attacks of hereditary angioedema in adults, expands the company's generic drug portfolio. Icatibant Injection is supplied as a prefilled, single-use syringe that is self-administered subcutaneously at the patient's home or doctor's office. In conjunction with launching its first specialty IV drug in the U.S., Fresenius Kabi is also launching KabiCare in the U.S., a comprehensive patient support program with case managers, co-pay assistance programs, injection training, and a patient assistance program.
Fresenius SE & Co. KGaA published this content on 01 December 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 December 2020 15:20:01 UTC